Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 19/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18613617 | 0.89 | FYN (0.58) | FYN | |
| SCHEMBL2946667 | 0.85 | FYN (0.50) | FYN | |
| SCHEMBL2948418 | 0.85 | FYN (0.57) | FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL4691714 | 0.83 | FYN (0.39) | FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL2951022 | 0.81 | DYRK3 (0.53) | FYN | |
| SCHEMBL2951390 | 0.81 | FYN (0.54) | FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL20486254 | 0.80 | NTRK1 (0.41) | FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL1049125 | 0.79 | PIK3CG (0.60) | FYN | |
| SCHEMBL2947614 | 0.78 | FYN (0.54) | FYN | |
| SCHEMBL18613356 | 0.78 | FYN (0.65) | FYNNTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | claimed |
| EP-3347462-A1 | METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS | Lau, Warren C. (US) | 2018-07-18 | — | — | EP | claimed |
| WO-2017044623-A1 | METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS | LAU WARREN C (US) | 2017-03-16 | — | — | WO | claimed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | disclosed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | FYN 666/4885NTRK1 750/4885NTRK3 896/4885 |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885NTRK1 399/4885NTRK3 473/4885 |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885NTRK1 399/4885NTRK3 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.